🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.

Recruitingn/aAges 18 Years - 75 YearsAllThe First Affiliated Hospital of Guangzhou Medica…
NCT06843707 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of metabolomics in the diagnosis, prognosis, and therapeutic monitoring of lung cancer. By profiling metabolic alterations, this study aims to identify potential biomarkers for distinguishing benign and malignant lung nodules, predicting therapeutic efficacy, and assessing long-term prognosis. Key time points include initial screening for lung nodules, postoperative evaluation to predict treatment outcomes, and therapeutic monitoring to assess efficacy after medication or other interventions. Through these analyses, the study seeks to uncover underlying metabolic mechanisms and provide valuable insights into personalized lung cancer management.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Signing of the informed consent form; 2. Male or female, aged 18-75 years; 3. Patients with lung nodules confirmed by CT examination; 4. Good preoperative pulmonary function cooperation and complete reporting; 5. Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging; 6. The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month. Exclusion Criteria: 1. Poor preoperative pulmonary function cooperation or missing reports; 2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission; 3. The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month; 4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.); 5. Coexisting with other severe functional impairments; 6. Patients with obstructive lesions such as airway or esophageal stenosis; (8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.
💊

What it tests

  • Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.
📍

Where

1 site
the First Affiliated of Guangzhou Medical University
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy